Search Results

You are looking at 161 - 170 of 182 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

not make sense, particularly when the patient may require symptom-driven imaging studies for 20 years after completion of 5 years of tamoxifen. Depending on treatment and geographic location, our study found that 18% to 46% of patients received high

Full access

Ashish Rai, Xuesong Han, Zhiyuan Zheng, K. Robin Yabroff, and Ahmedin Jemal

Gen Intern Med 2002 ; 17 : 243 – 252 . 36. Kahn KL Schneider EC Malin JL . Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use . Med Care 2007 ; 45 : 431 – 439 . 37. Schneider EC

Full access

Hanna K. Sanoff, YunKyung Chang, Joseph M. Stavas, Til Stürmer, and Jennifer Lund

phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402) . Eur J Cancer 2008 ; 44 : 528 – 538

Full access

Dominik J. Ose, Richard Viskochil, Andreana N. Holowatyj, Mikaela Larson, Dalton Wilson, William A. Dunson Jr, Vikrant G. Deshmukh, J. Ryan Butcher, Belinda R. Taylor, Kim Svoboda, Jennifer Leiser, Benjamin Tingey, Benjamin Haaland, David W. Wetter, Simon J. Fisher, Mia Hashibe, and Cornelia M. Ulrich

, Fischer HD , Yun L , . Association between tamoxifen treatment and diabetes: a population-based study . Cancer 2012 ; 118 : 2615 – 2622 . 10.1002/cncr.26559 21935915 47. Yennurajalingam S , Frisbee-Hume S , Palmer JL

Full access

Jason Hu, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir

therapy, such as aromatase inhibitors or tamoxifen, should undergo baseline BMD tests given the effect of those drugs on BMD. 42 Given the contextual similarity between patients with breast cancer and those with PCa treated with hormonal therapy, it is

Full access

Phillip G. Febbo, Marc Ladanyi, Kenneth D. Aldape, Angelo M. De Marzo, M. Elizabeth Hammond, Daniel F. Hayes, A. John Iafrate, R. Kate Kelley, Guido Marcucci, Shuji Ogino, William Pao, Dennis C. Sgroi, and Marian L. Birkeland

Dowsett M Allred C Knox J . Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial . J Clin

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes

), early age at menarche, nulliparity, late age at menopause, Lynch syndrome, older age (≥55 years), and tamoxifen use. 3 - 6 Thus, the incidence of endometrial cancer is increasing because of increased life expectancy and obesity. For patients with

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

tamoxifen use. 4 – 7 Thus, the incidence of endometrial cancer is increasing because of increased life expectancy and obesity. The “Summary of the Guidelines Updates” (available at NCCN.org ) describes the most recent revisions to the algorithms, which

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee, and Anaadriana Zakarija

ambulatory cancer patients undergoing chemotherapy. Increased VTE risk was shown to be associated with the use of exogenous estrogen compounds, such as selective estrogen receptor modulators (e.g., tamoxifen, raloxifene), for the prevention and treatment of

Full access

Jessica K. DeMartino

,N0,M0, or stage II or III hormone receptor-negative breast cancer. NQF #0220: Tamoxifen or third-generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c,N0,M0, or stage II or III